ALK and non-small cell lung carcinoma: In conclusion, consistent with clinical trial data and real-world studies, lorlatinib was highly efficacious in terms of ORR, median PFS and median OS in this small real-world cohort of advanced ALK+ve NSCLC with manageable safety profile.